LIGAND PHARMACEUTICALS INC

Ligand Pharmaceuticals is a biopharmaceutical company that develops and licenses pharmaceutical assets across multiple therapeutic areas. The company's marketed portfolio includes products for infectious disease (Posaconazole, Voriconazole, NOXAFIL), oncology (KYPROLIS for multiple myeloma, QARZIBA for neuroblastoma), vaccines (PNEUMOSIL, VAXNEUVANCE, MenFive), endocrinology (Teriparatide for osteoporosis, Duavee for menopause), and specialty care (VEKLURY for COVID-19, TZIELD for type 1 diabetes). The company also maintains an active pipeline of compounds in development across respiratory, kidney, hepatic, ophthalmologic, and CNS indications.

Ligand's business model centers on acquiring, developing, and licensing biopharmaceutical assets globally. The company generates revenue through both marketed products and license agreements with other pharmaceutical manufacturers. Its product portfolio spans approximately 30 marketed therapies addressing conditions in oncology, immunology, infectious disease, rare disease, and metabolic disorders.

Based in Jupiter, Florida, Ligand operates with approximately 68 full-time employees and maintains a market capitalization of $3.8 billion. The company has a global presence, licensing and commercializing its products worldwide through both direct sales and partnership arrangements with other pharmaceutical entities.